We are live on ! Find out more
PAI

ProQuest Associates IV Portfolio holdings

AUM $53M
1-Year Est. Return 3.35%
This Fund
S&P 500
This Quarter Est. Return
+4.08%
1 Year Est. Return
+3.35%
3 Year Est. Return
+113.14%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$65M
AUM Growth
-$22M
Cap. Flow
-$17.9M
Cap. Flow %
-27.47%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
URGN icon
1
UroGen Pharma
URGN
$2.13B
$39.3M 60.44%
789,297
-306,727
-28% -$17.9M
MRSN
2
DELISTED
Mersana Therapeutics
MRSN
$17.1M 26.27%
38,228
– –
IMDZ
3
DELISTED
Immune Design Corp.
IMDZ
$5.63M 8.66%
1,236,394
– –
AGRX
4
DELISTED
Agile Therapeutics
AGRX
$2.5M 3.85%
2,531
– –
EGRX
5
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$513K 0.79%
6,777
– –

Similar funds

CCP
Centaur Capital Partners Southlake, Texas $54.1M AUM 12.4% 1-Year Est. Return
CLA
Cranberry Lake Advisors Houston, Texas $50.6M AUM 5.12% 1-Year Est. Return
HC
Hampstead Capital London, United Kingdom $55.8M AUM 2.76% 1-Year Est. Return
SF
Schooner Foundation Boston, Massachusetts $49.6M AUM 9.4% 1-Year Est. Return
DIV
DCM International V Menlo Park, California $47.8M AUM 19.52% 1-Year Est. Return
MGPI
Maveron General Partner III Seattle, Washington $46.7M AUM 35.29% 1-Year Est. Return
MCAI
Meritech Capital Associates III Palo Alto, California $45.8M AUM 24.9% 1-Year Est. Return
P
PhaseCapital New York $45.2M AUM 8.85% 1-Year Est. Return

ProQuest Associates IV's Q2 2018 Portfolio in Review

As of Q2 2018, ProQuest Associates IV held 5 positions worth $65M, down 25% from $87M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ProQuest Associates IV withdrew a net $17.9M in Q2 2018, reducing 1 holding. Its largest reduction was UroGen Pharma, cutting an estimated $17.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ProQuest Associates IV's biggest Q2 2018 reduction was UroGen Pharma, cutting an estimated $17.9M.
  • ProQuest Associates IV's ten largest holdings make up 100% of its $65M portfolio in Q2 2018.
  • ProQuest Associates IV opened 0 new positions and closed 0 in Q2 2018.
  • ProQuest Associates IV's portfolio value fell 25% quarter-over-quarter to $65M.

Based on ProQuest Associates IV's 13F filing for Q2 2018, filed 14 Aug 2018.